Christian Hampp
Overview
Explore the profile of Christian Hampp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hampp C, Lovegrove M, Budnitz D, Mathew J, Ho A, McAninch J
Drug Saf
. 2019 Nov;
43(2):189-191.
PMID: 31745829
No abstract available.
12.
Choi Y, Park H, Hampp C, Brumback B, Meissner H, Li Y, et al.
Pharmacoepidemiol Drug Saf
. 2019 Nov;
29(1):30-38.
PMID: 31737976
Background: The completeness of medical encounters capture among Medicaid enrollees in comprehensive managed care (CMC) has been shown to vary across states and years. CMC penetration has grown, and CMC...
13.
Pratt N, Mack C, Meyer A, Davis K, Hammill B, Hampp C, et al.
Pharmacoepidemiol Drug Saf
. 2019 Nov;
29(1):9-17.
PMID: 31736248
Purpose: The purpose of this paper is to provide guidance on the evaluation of data linkage quality through the development of a checklist for reporting key elements of the linkage...
14.
Hampp C, Swain R, Horgan C, Dee E, Qiang Y, Dutcher S, et al.
Diabetes Care
. 2019 Oct;
43(1):90-97.
PMID: 31601640
Objective: To estimate real-world off-label use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes, estimate rates of diabetic ketoacidosis (DKA), and compare them with DKA rates...
15.
Knox C, Hampp C, Palmsten K, Zhu Y, Setoguchi S, Brumback B, et al.
Pharmacoepidemiol Drug Saf
. 2019 Jul;
28(9):1222-1230.
PMID: 31286606
Purpose: The state-assigned Case ID number in the Medicaid Analytic eXtract (MAX) allows for potential linkage of mothers to infants. No validation of respective linkage algorithms is available. We established...
16.
Bird S, Toh S, Sahin L, Andrade S, Gelperin K, Taylor L, et al.
Am J Epidemiol
. 2018 Oct;
188(2):418-425.
PMID: 30321259
Letrozole is an aromatase inhibitor that has an unapproved use for ovulation induction with infertility. Because of the proximity of this use to conception, we selected letrozole to study the...
17.
Illoh O, Toh S, Andrade S, Hampp C, Sahin L, Gelperin K, et al.
Pharmacoepidemiol Drug Saf
. 2018 Mar;
27(6):604-611.
PMID: 29516585
Purpose: To describe the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre-pregnancy period. Methods: We identified live-born deliveries...
18.
Toh S, Reichman M, Graham D, Hampp C, Zhang R, Butler M, et al.
Diabetes Care
. 2017 Nov;
41(1):39-48.
PMID: 29122893
Objective: The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. We prospectively examined the association between saxagliptin use and acute myocardial...
19.
Gagne J, Houstoun M, Reichman M, Hampp C, Marshall J, Toh S
Pharmacoepidemiol Drug Saf
. 2017 Nov;
27(1):30-37.
PMID: 29108128
Purpose: The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the...
20.
Bird S, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade S, et al.
Drug Saf
. 2017 Aug;
41(1):87-94.
PMID: 28840499
Introduction: Pregnancy registries and spontaneous reports are essential pharmacovigilance tools to evaluate drug safety during pregnancy. Objectives: The aim of this study was to evaluate postmarket capture of exposed pregnancies....